arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Kairos Pharma, LTD.

KAPA

$0.38 ▼ -0.01 (-1.92%) at close

13 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Kairos Pharma, LTD. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -25.1% ↘

FCF / Share $-0.05

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-1.65M

↓ -31.1% —

FCF / Share Free cash flow per share

$-0.05

↓ -9.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	12.5% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	30.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-300.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-166.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	20.0% Good Good Year-over-year change in earnings per share Optimal: > 10%	-233.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-31.1% Weak ↑ Weak Improving Year-over-year change in net income	-39.3% Weak ↑ Weak Improving Year-over-year change in net income	-33.5% Weak ↑ Weak Improving Year-over-year change in net income	-462.1% Weak ↓ Weak Declining Year-over-year change in net income	-290.7% Weak ↓ Weak Declining Year-over-year change in net income	12.3% Fair Fair Year-over-year change in net income	-235.6% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-9.6% Weak Weak Year-over-year change in free cash flow	—	—	-194.0% Weak Weak Year-over-year change in free cash flow	N/M	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.63x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.84x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.66x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.11x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.06x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-25.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-19.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.6% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	9.4% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	41.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	12.1% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-29.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-25.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-7.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-112.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-31.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-308%)	-21.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-18.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-222%)	-23.7% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-258%)	-17.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-218%)	-20.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-237%)	-31.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-309%)	9.5% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-36%)	13.5% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-10%)	53.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+259%)	16.7% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+11%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-3.67M	$-4.49M	$-5.58M	$-3.03M	$-3.62M	$-1.27M	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.08	$-0.07	$-0.07	$-0.08	$-0.08	$-0.08	$-0.10	$-0.02	$-0.03	$-0.10	$-0.03	—	—
Free Cash Flow per Share (USD)	$-0.05	—	$-0.04	$-0.05	$-0.04	—	—	$-0.02	$0.00	—	—	—	—
Book Value per Share (USD)	$0.25	$0.30	$0.37	$0.34	$0.45	$0.35	$0.26	$-0.25	$-0.23	$-0.20	$-0.18	—	—
Tangible Book Value per Share (USD)	$0.25	$0.30	$0.36	$0.33	$0.44	$0.33	$0.24	$-0.25	$-0.23	$-0.23	$-0.18	—	—
Basic Weighted Avg Shares (shares)	21.01M	—	20.21M	17.21M	15.88M	—	10.91M	10.56M	10.56M	—	10.33M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$4.01M	$5.19M	$6.25M	$4.16M	$5.25M	$3.18M	$3.07M	—	—	$-2.30M	—	—	—
Total Equity (USD)	$5.31M	$6.34M	$7.66M	$6.00M	$7.13M	$4.78M	$3.33M	$-2.65M	$-2.40M	$-2.08M	$-1.87M	$-1.56M	$-1.18M

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Income, GAAP (USD)	$-1.65M	$-1.36M	$-1.40M	$-1.42M	$-1.26M	$-980.00K	$-1.05M	$-253.00K	$-323.00K	$-1.12M	$-312.00K	—	—
Operating Cash Flow (USD)	$-1.04M	$-1.08M	$-838.00K	$-805.00K	$-714.00K	$-1.80M	—	$-168.00K	$36.00K	$66.00K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 13 quarters

Kairos Pharma, LTD.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KAPA with peers